Levolta Pharmaceuticals has entered into an exclusive licensing and distribution agreement with Tabuk Pharmaceutical for commercialising VOLT01, an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region.
02 Jun 2023
30 May 2023
Italy-based Abiogen Pharma has announced the acquisition of a 97.09% stake in Switzerland-based EffRx Pharmaceuticals.
03 Sep 2021
The US Food and Drug Administration (FDA) has granted fast track designation for Novartis’ agonist LNA043 to treat knee osteoarthritis.
09 Apr 2021
Biogen and Bio-Thera Solutions have entered into a commercialisation and license agreement for the development, manufacturing and commercialisation of BAT1806.
08 Apr 2021
AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of adults with active psoriatic arthritis.
18 Mar 2021
The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.